Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MabionCD20 versus MabThera bioequivalence trial in diffuse large B-cell lymphoma
2013-005506-56Phase 3Completed
- Sponsor
- Mabion S.A.
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing MabionCD20 with MabThera (2 arms). Primary endpoint: Area under the plasma concentration-time curve from time zero to final time point (AUC 0-t). Started Jul 2014; status: completed.
02
Drugs
MabionCD20rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2013-005506-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005506-56.